Table 1 Demographics and baseline characteristics (FAS P1 , FAS P2 )
PERIOD 1 | ||
|---|---|---|
Placebo | 300IR | |
N = 261 | N = 275 | |
Age (years) | 36.6 (11.26) | 38.6 (10.97) |
Gender (n and % female) | 137 (52.5) | 141 (51.3) |
Duration of allergic rhinoconjunctivitis (years) | 13.7 (10.72) | 14.2 (10.52) |
Presence of Oral Allergy Syndrome (n, %) | 141 (54.0) | 150 (54.5) |
FEV1 (% predicted) | 100.7 (11.82) | 101.8 (13.80) |
RRTSS | 14.2 (1.62) | 14.4 (1.75) |
Presence of asthma (n, %) | 75 (28.7) | 58 (21.1) |
Poly-sensitized* (n, %) | 179 (68.6) | 205 (74.5) |
PERIOD 2 | ||
Placebo | 300IR | |
N = 247 | N = 253 | |
Age (years) | 36.7 (11.33) | 38.4 (11.05) |
Gender (n and % female) | 129 (52.2) | 132 (52.2) |
Duration of allergic rhinoconjunctivitis (years) | 13.4 (10.39) | 13.8 (10.49) |
Presence of Oral Allergy Syndrome (n, %) | 133 (53.8) | 138 (54.5) |
FEV1 (% predicted) | 100.8 (12.05) | 102.1 (13.58) |
RRTSS | 14.2 (1.60) | 14.4 (1.75) |
Presence of asthma (n, %) | 70 (28.3) | 54 (21.3) |
Poly-sensitized* (n, %) | 169 (68.4) | 185 (73.1) |